Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model
- Min-Jung Park†1,
- So-Youn Min†1,
- Kyung-Su Park1, 2,
- Young-Gyu Cho1,
- Mi-La Cho1,
- Young-Ok Jung1,
- Hyun-Sil Park1,
- Soog-Hee Chang1,
- Seok Goo Cho3,
- Jun-Ki Min1, 2,
- Sung-Hwan Park1, 2 and
- Ho-Youn Kim1, 2Email author
© Park et al.; licensee BioMed Central Ltd. 2008
Received: 12 April 2007
Accepted: 25 January 2008
Published: 25 January 2008
The present study was devised to understand the role of systemic indoleamine 2,3-dioxygenase (IDO) in the tolerance induction for orally tolerized mice in collagen-induced arthritis (CIA). We examined whether IDO-expressing dendritic cells (DCs) are involved in the generation of CD4+CD25+ regulatory T cells during the induction of oral tolerance in a murine CIA model.
Type II collagen was fed six times to DBA/1 mice beginning 2 weeks before immunization, and the effect on arthritis was assessed. To examine the IDO expression, the DCs of messenger RNA and protein were analyzed by RT-PCR and Flow cytometry. In addition, a proliferative response assay was also carried out to determine the suppressive effects of DCs through IDO. The ability of DCs expressing IDO to induce CD4+CD25+ T regulatory cells was examined.
CD11c+ DCs in Peyer's patches from orally tolerized mice expressed a higher level of IDO than DCs from nontolerized CIA mice. IDO-expressing CD11c+ DCs were involved in the suppression of type II collagen-specific T-cell proliferation and in the downregulation of proinflammatory T helper 1 cytokine production. The suppressive effect of IDO-expressing CD11c+ DCs was mediated by Foxp3+CD4+CD25+ regulatory T cells.
Our data suggest that tolerogenic CD11c+ DCs are closely linked with the induction of oral tolerance through an IDO-dependent mechanism and that this pathway may provide a new therapeutic modality to treat autoimmune arthritis.
Repeated oral administration of autoantigen can suppress autoimmune responses in collagen-induced arthritis (CIA) and experimental autoimmune encephalomyelitis, and can suppress diabetes in nonobese diabetic mice [1–10]. Although the mechanisms responsible for the induction of oral tolerance have not been elucidated fully, repeated oral administration of a high dose of antigen can induce oral tolerance by anergy or deletion of antigen-specific T cells. In contrast, repeated feeding of a low dose of antigen favors the induction of active immune regulation involving regulatory T cells, including transforming growth factor beta (TGFβ)-producing T helper 3 cells, IL-10-producing T regulatory 1 cells, and CD4+CD25+ T cells [1, 10, 11]. Previous studies have demonstrated that, after repeated oral administration of type II collagen (CII) and subsequent induction of CIA, the mean arthritis index is lower in tolerized mice than in CIA mice  and the proportion of IL-10-producing CD4+CD25+ T cells increases in Peyer's patches and spleens of tolerized mice . Among the various immune cells involved in the induction of oral tolerance, dendritic cells (DCs) may play a major role in linking orally administered antigen to antigen-specific tolerance.
DCs are professional antigen-presenting cells (APCs) that play a decisive role in determining immunity or immune tolerance; this determination is based on the maturation or activation state and the subset of DCs, and cytokine profiles in the microenvironment at the time of antigen uptake [1, 14–16]. A previous study demonstrated that CD11c+CD11b+ DCs, which increase in number in Peyer's patches during the induction of tolerance to CII, suppress T-cell proliferation and induce CD4+CD25+ regulatory T cells. CD11c+CD8α+ DCs, however, promote T-cell proliferation . The mechanisms underlying the suppression by DCs of the expansion and differentiation of effector T cells and promotion of T-cell tolerance remain elusive.
One regulatory mechanism of DCs is the suppression of proliferation by producing the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan. Murine macrophages and DCs expressing IDO inhibit T-cell proliferation or induce T-cell apoptosis in vitro and in vivo . Munn and colleagues reported that plasmacytoid DCs in tumor-draining lymph nodes express IDO constitutively, which causes local immunosuppression and T-cell anergy in vivo [18, 19]. Mellor and colleagues reported that systemic administration of CpG oligodeoxynucleotides induces IDO expression in splenic CD19+ DCs, which acquire regulatory functions in an IDO-dependent manner . Upon exposure to allergen within the mucosa, Langerhans-like DCs expressing high-affinity IgE receptors produce IL-10 and TGFβ, upregulate IDO expression, and suppress the allergic response in humans [16, 21, 22]. Whether the tolerogenic activity of DCs from Peyer's patches in orally tolerized mice is IDO dependent, however, is unknown.
To elucidate the expression of IDO and its role in the induction of oral tolerance, we prepared DCs from Peyer's patches of DBA/1 mice after induction of oral tolerance by repeated oral administration of CII and subsequent induction of CIA. We examined whether IDO-expressing DCs have tolerogenic characteristics and whether they can induce CD4+CD25+ regulatory T cells. Our results demonstrate that IDO-expressing DCs in Peyer's patches play an essential role in the induction of oral tolerance in this model of autoimmune disease.
Materials and methods
Six-week-old to 8-week-old male DBA/1J mice (SLC, Inc., Shizuoka, Japan) were maintained in groups of two to four animals in polycarbonate cages in a specifically pathogen-free environment and were fed standard mouse chow (Ralston Purina, St Louis, MO, USA) and water ad libitum. All experimental procedures were examined and approved by the Animal Research Ethics Committee at the Catholic University of Korea.
Preparation of type II collagen
Bovine CII was kindly provided by Professor Andrew Kang of the University of Tennessee. CII was extracted in its native form from the fetal calf articular cartilage and was purified as described previously .
Induction of oral tolerance in DBA/1 mice
DBA/1 mice were sacrificed either with 100 μg bovine CII dissolved in 0.05 N acetic acid and 4 mg/ml solution of 25 μl CII solution + 175 μl PBS for the tolerance group or with an equal volume of an acetic acid–PBS mixture (25 μl of 0.05 N acetic acid + 175 μl PBS) for the CIA group. Administration was performed using an oral Zonde needle (Natsume, Tokyo, Japan) every 2 days over 2 weeks, beginning 2 weeks before immunization.
Induction and evaluation of arthritis
Bovine CII was dissolved in 0.05 N acetic acid to 4 mg/ml concentration and was emulsified (1:1 ratio) with complete Freund's adjuvant. As a primary immunization, 0.1 ml emulsion containing 100 μg CII was injected into the tail. Two weeks later, a booster injection of 100 μg CII dissolved similarly and emulsified 1:1 with incomplete Freund's adjuvant was administered to the hind leg.
Starting 18 days after the primary immunization, three independent observers examined the severity of arthritis three times a week for up to 11 weeks. The severity of arthritis was recorded as the mean arthritic index on a 0 to 4 scale according to the following criteria : 0 = no edema or swelling, 1 = slight edema and erythema limited to the foot or ankle, 2 = slight edema and erythema from the ankle to the tarsal bone, 3 = moderate edema and erythema from the ankle to the tarsal bone, and 4 = edema and erythema from the ankle to the entire leg. The sum of the values from three legs, excluding the hind leg into which CII–incomplete Freund's adjuvant was injected, was determined and divided by three to obtain an average. The final value represents the average recorded by three independent observers.
Isolation of dendritic cells
Mononuclear cells from Peyer's patches were incubated with anti-mouse CD11c-coated magnetic beads (Miltenyi Biotec, Auburn, CA, USA) and then subjected to positive selection through magnetic-activated cell sorting. Separated cells routinely showed >98% viable DCs.
Determination of the type II collagen-specific T-cell proliferative response
Mice were killed 5 weeks after primary immunization. The Peyer's patches were removed, treated for 90 minutes at 37°C with media containing dithiothreitol and ethylenediamine tetraacetic acid to remove epithelial cells, and washed extensively with Hanks' balanced salt solution. The Peyer's patches were then digested with collagenase D and DNase, and were incubated in the presence of 5 mM ethylenediamine tetraacetic acid for 5 minutes at 37°C. Prepared mononuclear cells were then plated in 96-well microtiter plates at a concentration of 2 × 105 cells/well and cultured for 3 days with 40 μg/well CII in 0.3 ml Click's medium supplemented with 0.5% mouse serum. CD11c+ DCs (1 × 104 cells) isolated from Peyer's patch mononuclear cells of tolerized or CIA mice were cultured for 3 days with CII-reactive CD4+ T cells (1 c 105 cells) and irradiated APCs (1 × 105 cells) obtained from Peyer's patch cells of CIA mice. Cells were pretreated with the IDO-specific inhibitor 1-methyl tryptophan (1-MT) (200 μM) for 2 hours before CII stimulation. Eighteen hours before the termination of culture, 0.5 μCi [3H]thymidine (New England Nuclear, Boston, MA, USA) was added to each well. Cells were harvested onto glass fiber filters and were counted in a Matrix-96 direct ionization counter (Packard Instrument Co., Downers Grove, IL, USA). Data are presented as the mean counts per minute (cpm) of triplicate cultures.
Various numbers of CD4+CD25+ T cells that had been expanded by exposure to CD11c+ DCs from Peyer's patches of tolerized mice in the presence of CII stimulation were cultured for 3 days in the presence of CII (40 μg/well) with CII-reactive CD4+ T cells (1 × 105 cells) and irradiated APCs (1 × 105 cells) obtained from CIA mice. Proliferative responses were measured as the amount of [3H]thymidine incorporated during the last 18 hours of incubation.
Reverse transcription–polymerase chain reaction analysis of indoleamine 2,3-dioxygenase and Foxp3 expression
Total RNA (2 μg) was reverse transcribed into cDNA using a transcription kit (TaqMan Reverse Transcription Reagents; Applied Biosystems, Darmstadt, Germany). The resulting cDNA was amplified by PCR using IDO sense (5'-CACTGTACCAGTGCAGTAG-3') and antisense (5'-ACCATTCACACACT CGTTAT-3') primers, and using Foxp3 sense (5'-CAGCTGCCTACAGTGCCCCTAG-3') and antisense (5'-CATTTGCCACGAGTGGGTAG-3') primers. PCR products were separated on a 1.5% agarose gel and stained with ethidium bromide. Fragments of 472 bp for IDO and 390 bp for Foxp3 were obtained.
Detection of cytokine production by enzyme-linked immunosorbent assay
CD4+ T cells isolated from Peyer's patches of CIA mice were cocultured with CD11c+ DCs from tolerized mice or CIA mice in the absence or presence of CII (40 μg/well). Cells were pretreated for 2 hours with 1-MT (200 μM). After 2 days, the culture medium was harvested from each well and stored at -70°C. The concentrations of IL-17, IL-10, and TGFβ in the culture supernatant were measured by sandwich ELISA.
Flow cytometric analysis of intracellular indoleamine 2,3-dioxygenase and regulatory T cells
Single mononuclear cells were prepared from Peyer's patches of tolerized and CIA mice, stained with Fluorescein isothiocyanate-labeled anti-CD11c mAb, permeabilized, and fixed with CytoPerm/CytoFix (Pharmingen, BD, San Diego, CA, USA) as instructed by the manufacturer. Cells were stained further with rabbit anti-IDO polyclonal antibody (Transgenic Inc, Kobe, Japan), followed by Phycoerythrin-conjugated goat anti-rabbit immunoglobulin, and then subjected to flow cytometric analysis (FACSCalibur; Becton Dickinson, San Jose, CA, USA). Rabbit IgG was used as the corresponding isotype antibody control.
To isolate CD4+CD25- T cells, mononuclear cells from Peyer's patches from tolerized mice were stained with a mixture of anti-CD4 PerCP and CD25 allophycocyanin mAbs (Pharmingen, BD) and were sorted using the Vantage FACSorter (BD Bioscience, San Diego, CA). The purity of the sorted cells was 95% to 99% as evaluated by flow cytometry. CD11c+ DCs (1 × 104 cells) isolated from Peyer's patch mononuclear cells of tolerized or CIA mice were cultured for 3 days with CD4+CD25- T cells (1 × 105 cells) obtained from Peyer's patch cells of tolerized mice in the presence or absence of CII. To measure the amount of intracellular Foxp3 in CD4+CD25+ T cells, CD4+ T cells and DCs were cocultured and surface-stained with PerCP-labeled anti-mouse CD4 and allophycocyanin-labeled anti-mouse CD25, and then with 0.5 μg Phycoerythrin-conjugated anti-mouse Foxp3 or Phycoerythrin-conjugated rat IgG2a isotype control using the regulatory T Cell Staining Kit (eBioscience, San Diego, CA, USA).
Intracellular immunofluorescence staining was performed using the intracellular flow cytometric method described above. The cells were allowed to adhere to the glass slide using a Shandon CytoSpin III cytocentrifuge (GMI, Ramsey, MN, USA). The slides were then mounted using fluorescent mounting medium (Dako, Trappes, France). Confocal analysis was performed with a confocal laser scanning microscope (LSM 510 meta; Carl Zeiss, Heidelberg, Germany) equipped with a krypton–argon mixed-gas laser as the light source.
The arthritis scores at the different times were compared between the two groups using the nonparametric Mann–Whitney U test. All data are expressed as the mean ± standard deviation. Statistical analysis was performed using SPSS 10.0 for Windows (SPSS, Chicago, IL, USA). The differences between groups were analyzed using an unpaired Student's t test, assuming equal variances. P < 0.05 was considered significant.
Repeated oral administration of type II collagen induces immune tolerance and inhibits arthritis development
Induction of oral tolerance increases the proportion of indoleamine 2,3-dioxygenase-expressing CD11c+dendritic cells in Peyer's patches of tolerized mice
DCs are potent stimulators of naïve T cells and are key inducers of immune tolerance . One molecular mechanism by which DCs regulate T cells is through the expression of IDO, which degrades the essential amino acid tryptophan . To determine whether IDO expression increases in tolerized mice, we examined the relative proportion of IDO+ DCs among CD11c+ DCs in Peyer's patches after repeated oral administration of CII and subsequent CIA induction.
Using confocal microscopy, we identified the expression of IDO in situ at the single-cell level. Single cells were stained simultaneously with a pandendritic cell marker, anti-CD11c (green), and an IDO-specific antibody (red). About one-third of the CD11c+ DCs from tolerized mice expressed IDO (yellow). In contrast, the DCs from CIA mice rarely expressed IDO (Figure 2c).
Indoleamine 2,3-dioxygenase-expressing CD11c+dendritic cells have an immature phenotype
Human IDO+ DCs show a mature phenotype characterized by CD14-, CD83+, CD80+, CD86high, and HLA-DRhigh [27, 28]. In contrast, DCs expressing IDO in mice show an immature phenotype and suppress T-cell proliferation both in vitro and in vivo. The maturational status of IDO-expressing DCs in Peyer's patches of tolerized mice, however, has never been considered.
CD11c+dendritic cells of tolerized mice inhibit type II collagen-specific T-cell proliferation in an indoleamine 2,3-dioxygenase-dependent manner
APC-induced T-cell activation requires contact-dependent bidirectional signaling between the APCs and the T cells . This signaling may upregulate IDO expression in DCs, and this may control autoreactive T cells by depleting tryptophan [25, 30]. We explored whether IDO affects the ability of DCs isolated from Peyer's patches of tolerized mice to regulate T-cell responses. Mixed lymphocyte cultures were performed in the presence or absence of the IDO-specific inhibitor 1-MT. CD11c+ DCs from Peyer's patches of tolerized mice or CIA mice were cocultured for 3 days with CII-reactive CD4+ T cells and irradiated APCs obtained from CIA mice in the absence or presence of CII.
To investigate the effect of IDO on the suppression of antigen-specific T cells exerted by CD11c+ DCs from tolerized mice, cytokine concentrations were measured in the coculture supernatants. The IL-17 concentration was significantly lower in the culture supernatants of CD11c+ DCs of tolerized mice than in the supernatants of CD11c+ DCs of CIA mice cultured in the presence of CII (82 ± 17 pg/ml versus 158 ± 9 pg/ml, P < 0.05) (Figure 4b). Addition of 1-MT into the coculture in the presence of CII, however, markedly increased the production of IL-17 by tolerized CD11c+ DCs (from 82 ± 17 pg/ml to 141 ± 15 pg/ml, P < 0.01). The concentrations of anti-inflammatory cytokines such as IL-10 and TGFβ were higher in the culture supernatants of CD11c+ DCs of tolerized mice than in the supernatants of CD11c+ DCs of CIA mice (IL-10, 131 ± 14 pg/ml versus 79 ± 13 pg/ml (P < 0.05); and TGFβ, 260 ± 11 pg/ml versus 195 ± 16 pg/ml (P < 0.05)). The addition of 1-MT, however, significantly decreased the production of IL-10 and TGFβ in the tolerance group (IL-10, from 131 ± 14 pg/ml to 92 ± 16 pg/ml (P < 0.05); and TGFβ, from 260 ± 11 pg/ml to 126 ± 9 pg/ml (P < 0.05)), suggesting that IDO expression on CD11c+ DCs plays an important role in immune suppression.
Indoleamine 2,3-dioxygenase-dependent induction of antigen-specific CD4+CD25+ T cells by CD11c+dendritic cells in tolerized mice
Regulatory APCs may form a bridge between regulatory T cells and responder T cells, and this has been proposed as a mechanism contributing to the phenomenon of linked suppression and dominant tolerance . Experimental evidence indicates that murine regulatory T cells can induce the expression of IDO . We hypothesized that CD11c+ DCs in tolerized mice are likely to be the IDO-dependent biologically relevant trigger for the generation or conversion of CD4+CD25+ regulatory T cells. In a previous study, CD11c+CD11b+ DCs isolated from Peyer's patches of tolerized mice seemed necessary for the expansion and differentiation of CD4+CD25+ T cells, which suppress CII-specific T-cell proliferation . Highly purified CD4+CD25- T cells isolated from tolerized mice (purity > 99%) were cocultured with CD11c+ DCs from tolerized or CIA mice for 3 days, without CII. The proportion of CD4+CD25+ T cells expanded by CD11c+ DCs from tolerized mice was similar to that obtained by CD11c+ DCs from CIA mice (4.65% ± 0.66% versus 3.68% ± 0.46%). 1-MT had no significant effect on the proportion of CD4+CD25+ T cells in these systems (4.74% ± 0.91% versus 3.56% ± 0.33%).
To verify that the increased population of CD4+CD25+ Foxp3+ T cells retained their suppressive function, varying numbers of CD4+CD25+ T cells induced by exposure to CD11c+ DCs from tolerized mice were cocultured with CII-reactive CD4+ T cells and irradiated APCs from CIA mice for 3 days in the presence of CII. The CD4+CD25+ T cells induced by CD11c+ DCs inhibited the proliferative response of CII-reactive CD4+ T cells in a concentration-dependent manner (Figure 5e).
Oral tolerance is initiated in the gut-associated lymphoid tissues, a well-developed immune network in the alimentary tract that comprises the mucosal epithelium, lamina propria, Peyer's patches, and mesenteric lymph nodes [1, 2]. Peyer's patches are essential sites for the induction of mucosal immune responses and oral tolerance to soluble antigen, and Peyer's patch DCs are thought to play an important role in mucosal immunity and tolerance [1–4]. The selection between immunity and tolerance depends on several factors, including the occurrence of specialized DC subsets and the maturation state of the DCs [1, 12]. One mechanism, exploited by tolerogenic DCs, involves IDO [17–21]. IDO-competent DCs exert regulatory effects on T cells that are mediated by tryptophan depletion and by the production of metabolic byproducts collectively known as kynurenines [16, 21, 22].
Demonstrating the concomitant induction of IDO enzymatic activity by DCs, our data support IDO-dependent mechanisms that have been associated with induction of T-cell tolerance and immune inhibition in the induction of oral tolerance in the murine CIA model. We examined the change in the expression of IDO in CD11c+ DCs of Peyer's patches after repeated oral administration of CII and subsequent induction of CIA. In freshly isolated Peyer's patches, the proportion of CD11c+ IDO+ DCs was higher in tolerized mice than that in CIA mice. We found that IDO expression was induced most by oral CII feeding plus CII immunization, and that the expression of IDO did not correlate with disease severity. Next, we investigated whether the expression of IDO by DCs takes place during the initial phase of oral CII feeding or after the immunization with CII for CIA induction. In these studies, Peyer's patches were isolated from mice that had been fed with CII or PBS but not immunized with CII. We examined the expression of IDO in situ. The expression of IDO by DCs increased in Peyer's patches of CII-fed mice, even though these mice had not been immunized. In contrast, IDO+ DCs were rare in the Peyer's patches of PBS-fed mice (data not shown). Our results show that IDO is induced by oral CII feeding and enhances the induction of immune tolerance after oral administration of antigens.
The immunosuppressive mechanism of IDO is shared by several different cell types in the immune system [30, 32–36]. Splenic CD11c+CD19+ DCs found in the mice administered CpG oligodeoxynucleotides, human monocyte-derived macrophages, and in vitro-derived DCs induce IDO expression and inhibit T-cell proliferation. In this regard, it will be interesting to investigate IDO expression in different subsets of DCs from tolerized mice and to characterize their role in the induction and maintenance of immune tolerance.
Tolerogenic DCs are immature, maturation-resistant, or alternatively activated DCs that express surface MHC molecules and have a low ratio of costimulatory to inhibitory signals, such as IL-10, programmed death-ligand 1, CTLA4/CD28, and IDO [37, 38]. IDO expression is detected constitutively in human regulatory plasmacytoid DCs and can be induced by classical DC maturation stimuli, namely IFNγ and lipopolysaccharide or prostaglandin E2, which contribute to their immunoregulatory capacity [37–40]. In our study, the phenotype of DCs from tolerized mice showed an immature tolerogenic state and low levels of surface MHC II and CD86 molecules, and expressed high levels of IDO compared with DCs from CIA mice. Our study suggests that IDO is expressed constitutively in immature DCs upon repeated oral administration of CII in an animal model without artificial administration of CTLA-4 immunoglobulin or other DC-modifying agents.
Because IDO expression on DCs plays a crucial role in the induction of regulatory T cells and inhibition of the antigen-specific T-cell response, we performed mixed lymphocyte cultures to determine whether DCs isolated from Peyer's patches of tolerized mice and CIA mice have an IDO-dependent effect on CII-specific T cells. DCs from the tolerized mice inhibited the proliferation of CII-specific T cells and inflammatory cytokine production compared with DCs from CIA mice, and these suppressive effects were more evident after CII stimulation and were abrogated by addition of 1-MT, an IDO inhibitor. These findings suggest that the functional activities of IDO from tolerized mice could affect the T-cell response.
In the resting state, autoreactive T cells residing in the periphery are suppressed effectively by regulatory T cells, which are thought to prevent the development of autoimmune diseases . Our group previously demonstrated that the proportion of IL-10-producing CD4+CD25+ T cells increases more in Peyer's patches and spleens of tolerized mice than in those of CIA mice . Bozza and colleagues reported that CD4+CD25+ regulatory T cells in candidiasis are strictly dependent on the expression of B7 costimulatory molecules by IL-10-producing DCs, and are involved in the IFNγ/IDO-dependent pathway that controls the local inflammatory pathology . Saito and colleagues also found that CTLA-4 on CD4+CD25+ regulatory T cells induces the expression of IDO on DCs . Considering these findings, we next sought to determine whether IDO+ DCs increase the proportion of antigen-specific CD4+CD25+ regulatory T cells in tolerized mice. Figure 5 shows that the percentage of CD4+CD25+ cells increased significantly after coculture of CD4+CD25- T cells with CD11c+ DCs from tolerized mice in the presence of CII through an IDO-dependent mechanism. In the absence of CII, however, the proportion of CD4+CD25+ cells cocultured with CD11c+ DCs of tolerized mice was similar to that in cells cocultured with CD11c+ DCs from CIA mice. This result suggests that the conversion into CD4+CD25+ T cells without CII stimulation result from the IDO-independent expansion or selected survival of residual CD4+CD25+ T cells. Foxp3 is a transcription factor specific for CD4+CD25+ regulatory T cells. Foxp3 may be necessary for the induction of CD4+CD25+ regulatory T cells by conversion of CD4+CD25- T cells after antigen stimulation . We found that CD4+CD25+ T cells obtained after coculture of CD4+CD25- T cells and CD11c+ DCs of tolerized mice with CII expressed a large amount of Foxp3 transcript and Foxp3 protein in vitro in an IDO-dependent manner. In addition, the conversion of Foxp3+CD4+CD25+ T cells, which are thought to be regulatory T cells, inhibited the proliferation of CII-reactive CD4+ T cells in a dose-dependent manner.
CD4+CD25+ regulatory T cells converted from peripheral CD4+CD25- naïve T cells by TGFβ induction of Foxp3 were reported to be unresponsive to T-cell receptor stimulation, to produce neither T helper 1 nor T helper 2 cytokines, to express TGFβ, and to inhibit normal T-cell proliferation in vitro . Different to this regulatory T-cell population, we found that the Foxp3+CD4+CD25+ T cells in our model system may result partly from the expansion or selected survival of residual CD4+CD25+ regulatory T cells and partly from the conversion of CD4+CD25- T cells into Foxp3+CD4+CD25+ regulatory T cells through an IDO-dependent mechanism.
IDO expression by DCs is crucial for the induction of Foxp3+CD4+CD25+ T cells and for the suppression of CII-reactive T-cell function in induction of oral tolerance to CII. These results demonstrate that the induction of IDO+ DCs in Peyer's patches plays an essential role in the induction of oral tolerance and may provide a new modality of immune-based treatments for autoimmune diseases.
= antigen-presenting cell
= base pair
= collagen-induced arthritis
= type II collagen
= counts per minute
= dendritic cell
= enzyme-linked immunosorbent assay
- IDO = indoleamine 2:
= 1-methyl tryptophan
= monoclonal antibody
= major histocompatibility complex
= phosphate-buffered saline
= polymerase chain reaction
= reverse transcriptase
= transforming growth factor beta.
The authors are grateful to Professor Andrew H. Kang for providing the CII. This work was supported by a grant (R11-2002-098-01001-0) from the Korea Science and Engineering Foundation through the Rheumatism Research Center and by the Korean Research Foundation Grant (KRF-2005-217-E00003) funded by the Korean Government (MOEHRD, Basic Research Promotion Fund).
- Mayer L, Shao L: Therapeutic potential of oral tolerance. Nat Rev Immunol. 2004, 4: 407-419. 10.1038/nri1370.View ArticlePubMedGoogle Scholar
- Mowat AM: Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003, 3: 331-341. 10.1038/nri1057.View ArticlePubMedGoogle Scholar
- Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ: Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA. 1986, 83: 7443-7446. 10.1073/pnas.83.19.7443.PubMed CentralView ArticlePubMedGoogle Scholar
- Whitacre CC, Song F, Wardrop RM, Campbell K, McClain M, Benson J, Guan Z, Gienapp I: Regulation of autoreactive T cell function by oral tolerance to self-antigens. Ann N Y Acad Sci. 2004, 1029: 172-179. 10.1196/annals.1309.033.View ArticlePubMedGoogle Scholar
- Song F, Guan Z, Gienapp IE, Shawler T, Benson J, Whitacre CC: The thymus plays a role in oral tolerance in experimental autoimmune encephalomyelitis. J Immunol. 2006, 177: 1500-1509.View ArticlePubMedGoogle Scholar
- Dubois B, Goubier A, Joubert G, Kaiserlian D: Oral tolerance and regulation of mucosal immunity. Cell Mol Life Sci. 2005, 62: 1322-1332. 10.1007/s00018-005-5036-0.View ArticlePubMedGoogle Scholar
- Mowat AM, Parker LA, Beacock-Sharp H, Millington OR, Chirdo F: Oral tolerance: overview and historical perspectives. Ann N Y Acad Sci. 2004, 1029: 1-8. 10.1196/annals.1309.001.View ArticlePubMedGoogle Scholar
- Derry CJ, Harper N, Davies DH, Murphy JJ, Staines NA: Importance of dose of type II collagen in suppression of collagen-induced arthritis by nasal tolerance. Arthritis Rheum. 2001, 44: 1917-1927. 10.1002/1529-0131(200108)44:8<1917::AID-ART330>3.0.CO;2-W.View ArticlePubMedGoogle Scholar
- Garcia G, Komagata Y, Slavin AJ, Maron R, Weiner HL: Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J Autoimmun. 1999, 13: 315-324. 10.1006/jaut.1999.0320.View ArticlePubMedGoogle Scholar
- Weiner HL: Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997, 18: 335-343. 10.1016/S0167-5699(97)01053-0.View ArticlePubMedGoogle Scholar
- Friedman A, Weiner HL: Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA. 1994, 91: 6688-6692. 10.1073/pnas.91.14.6688.PubMed CentralView ArticlePubMedGoogle Scholar
- Min SY, Park KS, Cho ML, Kang JW, Cho YG, Hwang SY, Park MJ, Yoon CH, Min JK, Lee SH, Park SH, Kim HY: Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum. 2006, 54: 887-898. 10.1002/art.21647.View ArticlePubMedGoogle Scholar
- Min SY, Hwang SY, Park KS, Lee JS, Lee KE, Kim KW, Jung YO, Koh HJ, Do JH, Kim H, Kim HY: Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther. 2004, 6: R213-R219. 10.1186/ar1169.PubMed CentralView ArticlePubMedGoogle Scholar
- Kelsall BL, Leon F: Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunol Rev. 2005, 206: 132-148. 10.1111/j.0105-2896.2005.00292.x.View ArticlePubMedGoogle Scholar
- Mowat AM: Dendritic cells and immune responses to orally administered antigens. Vaccine. 2005, 23: 1797-1799. 10.1016/j.vaccine.2004.11.008.View ArticlePubMedGoogle Scholar
- Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H: Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003, 18: 605-617. 10.1016/S1074-7613(03)00113-4.View ArticlePubMedGoogle Scholar
- Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B, Keskin DB, Mellor AL, Fioretti MC, Grohmann U, Puccetti P: Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol. 2002, 14: 65-68. 10.1093/intimm/14.1.65.View ArticlePubMedGoogle Scholar
- Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004, 114: 280-290. 10.1172/JCI200421583.PubMed CentralView ArticlePubMedGoogle Scholar
- Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005, 22: 633-642. 10.1016/j.immuni.2005.03.013.View ArticlePubMedGoogle Scholar
- Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH: Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol. 2005, 175: 5601-5605.View ArticlePubMedGoogle Scholar
- Bilsborough J, George TC, Norment A, Viney JL: Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology. 2003, 108: 481-492. 10.1046/j.1365-2567.2003.01606.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Overtvelt L: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006, 61: 151-165. 10.1111/j.1398-9995.2006.01002.x.View ArticlePubMedGoogle Scholar
- Stuart JM, Cremer MA, Kang AH, Townes AS: Collagen-induced arthritis in rats. Evaluation of early immunologic events. Arthritis Rheum. 1979, 22: 1344-1351. 10.1002/art.1780221205.View ArticlePubMedGoogle Scholar
- Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE: Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 1998, 41: 290-297. 10.1002/1529-0131(199802)41:2<290::AID-ART13>3.0.CO;2-R.View ArticlePubMedGoogle Scholar
- Belz GT, Heath WR, Carbone FR: The role of dendritic cell subsets in selection between tolerance and immunity. Immunol Cell Biol. 2002, 80: 463-468. 10.1046/j.1440-1711.2002.01116.x.View ArticlePubMedGoogle Scholar
- Munn DH, Sharma MD, Mellor AL: Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004, 172: 4100-4110.View ArticlePubMedGoogle Scholar
- Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL, Mellor AL: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002, 297: 1867-1870. 10.1126/science.1073514.View ArticlePubMedGoogle Scholar
- Hwang SL, Chung NP, Chan JK, Lin CL: Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res. 2005, 15: 167-175. 10.1038/sj.cr.7290282.View ArticlePubMedGoogle Scholar
- Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS: CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol. 2004, 30: 311-318. 10.1165/rcmb.2003-0268OC.View ArticlePubMedGoogle Scholar
- Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003, 9: 1269-1274. 10.1038/nm934.View ArticlePubMedGoogle Scholar
- Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P: Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003, 4: 1206-1212. 10.1038/ni1003.View ArticlePubMedGoogle Scholar
- Yoshida R, Nukiwa T, Watanabe Y, Fujiwara M, Hirata F, Hayaishi O: Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. Arch Biochem Biophys. 1980, 203: 343-351. 10.1016/0003-9861(80)90185-X.View ArticlePubMedGoogle Scholar
- Malina HZ, Martin XD: Indoleamine 2,3-dioxygenase: antioxidant enzyme in the human eye. Graefes Arch Clin Exp Ophthalmol. 1996, 234: 457-462. 10.1007/BF02539413.View ArticlePubMedGoogle Scholar
- Moffett JR, Espey MG, Namboodiri MA: Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell Tissue Res. 1994, 278: 461-469. 10.1007/BF00331364.View ArticlePubMedGoogle Scholar
- Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH: Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest. 2003, 83: 1457-1466. 10.1097/01.LAB.0000090158.68852.D1.View ArticlePubMedGoogle Scholar
- Mellor AL, Munn DH: Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today. 1999, 20: 469-473. 10.1016/S0167-5699(99)01520-0.View ArticlePubMedGoogle Scholar
- Hubert P, Jacobs N, Caberg JH, Boniver J, Delvenne P: The cross-talk between dendritic and regulatory T cells: good or evil?. J Leukoc Biol. 2007, 82: 781-794. 10.1189/jlb.1106694.View ArticlePubMedGoogle Scholar
- Morelli AE, Thomson AW: Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007, 7: 610-621. 10.1038/nri2132.View ArticlePubMedGoogle Scholar
- Bozza S, Fallarino F, Pitzurra L, Zelante T, Montagnoli C, Bellocchio S, Mosci P, Vacca C, Puccetti P, Romani L: A crucial role for tryptophan catabolism at the host/Candida albicans interface. J Immunol. 2005, 174: 2910-2918.View ArticlePubMedGoogle Scholar
- Saito S, Sasaki Y, Sakai M: CD4(+)CD25high regulatory T cells in human pregnancy. J Reprod Immunol. 2005, 65: 111-120. 10.1016/j.jri.2005.01.004.View ArticlePubMedGoogle Scholar
- Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H: Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005, 6: 1219-1227. 10.1038/ni1265.View ArticlePubMedGoogle Scholar
- Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003, 198: 1875-1886. 10.1084/jem.20030152.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.